250 related articles for article (PubMed ID: 21898543)
1. Erythropoietin mediated bone formation is regulated by mTOR signaling.
Kim J; Jung Y; Sun H; Joseph J; Mishra A; Shiozawa Y; Wang J; Krebsbach PH; Taichman RS
J Cell Biochem; 2012 Jan; 113(1):220-8. PubMed ID: 21898543
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin couples hematopoiesis with bone formation.
Shiozawa Y; Jung Y; Ziegler AM; Pedersen EA; Wang J; Wang Z; Song J; Wang J; Lee CH; Sud S; Pienta KJ; Krebsbach PH; Taichman RS
PLoS One; 2010 May; 5(5):e10853. PubMed ID: 20523730
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin promotes bone formation through EphrinB2/EphB4 signaling.
Li C; Shi C; Kim J; Chen Y; Ni S; Jiang L; Zheng C; Li D; Hou J; Taichman RS; Sun H
J Dent Res; 2015 Mar; 94(3):455-63. PubMed ID: 25586589
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis.
Suresh S; Lee J; Noguchi CT
FASEB J; 2020 Sep; 34(9):11685-11697. PubMed ID: 32671900
[TBL] [Abstract][Full Text] [Related]
5. The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways.
Rölfing JH; Baatrup A; Stiehler M; Jensen J; Lysdahl H; Bünger C
Stem Cell Rev Rep; 2014 Feb; 10(1):69-78. PubMed ID: 24052411
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice.
Awida Z; Hiram-Bab S; Bachar A; Saed H; Zyc D; Gorodov A; Ben-Califa N; Omari S; Omar J; Younis L; Iden JA; Graniewitz Visacovsky L; Gluzman I; Liron T; Raphael-Mizrahi B; Kolomansky A; Rauner M; Wielockx B; Gabet Y; Neumann D
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233351
[TBL] [Abstract][Full Text] [Related]
7. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin directly stimulates osteoclast precursors and induces bone loss.
Hiram-Bab S; Liron T; Deshet-Unger N; Mittelman M; Gassmann M; Rauner M; Franke K; Wielockx B; Neumann D; Gabet Y
FASEB J; 2015 May; 29(5):1890-900. PubMed ID: 25630969
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
10. Pasteurella multocida toxin- induced osteoclastogenesis requires mTOR activation.
Kloos B; Chakraborty S; Lindner SG; Noack K; Harre U; Schett G; Krämer OH; Kubatzky KF
Cell Commun Signal; 2015 Sep; 13():40. PubMed ID: 26369790
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Regulatory-associated Protein of mTOR (Raptor)/Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice.
Dai Q; Xie F; Han Y; Ma X; Zhou S; Jiang L; Zou W; Wang J
J Biol Chem; 2017 Jan; 292(1):196-204. PubMed ID: 27879318
[TBL] [Abstract][Full Text] [Related]
12. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice.
Awida Z; Bachar A; Saed H; Gorodov A; Ben-Califa N; Ibrahim M; Kolomansky A; Iden JA; Graniewitz Visacovsky L; Liron T; Hiram-Bab S; Brines M; Gabet Y; Neumann D
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008482
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin in bone homeostasis-Implications for efficacious anemia therapy.
Lappin KM; Mills KI; Lappin TR
Stem Cells Transl Med; 2021 Jun; 10(6):836-843. PubMed ID: 33475252
[TBL] [Abstract][Full Text] [Related]
14. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
[TBL] [Abstract][Full Text] [Related]
15. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.
Lee KW; Yook JY; Son MY; Kim MJ; Koo DB; Han YM; Cho YS
Stem Cells Dev; 2010 Apr; 19(4):557-68. PubMed ID: 19642865
[TBL] [Abstract][Full Text] [Related]
17. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
18. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
19. Context-Dependent Skeletal Effects of Erythropoietin.
Hiram-Bab S; Neumann D; Gabet Y
Vitam Horm; 2017; 105():161-179. PubMed ID: 28629516
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin as a therapeutic target in osteoporosis.
Shen G; Ren H; Qiu T; Zhang Z; Zhao W; Yu X; Huang J; Tang J; Liang D; Yao Z; Yang Z; Jiang X
J Cell Physiol; 2018 May; 233(5):3929-3944. PubMed ID: 28834576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
